PPWP
VRTX icon

Premier Path Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Premier Path Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$870K Sell
1,751
-119
-6% -$52.7K 0.1% 185
2026
Q1 		$835K Buy
1,870
+62
+3% +$28.9K 0.11% 181
2025
Q4 		$820K Buy
1,808
+118
+7% +$50.9K 0.11% 185
2025
Q3 		$662K Sell
1,690
-145
-8% -$60.6K 0.09% 225
2025
Q2 		$817K Buy
1,835
+45
+3% +$20.7K 0.11% 190
2025
Q1 		$868K Buy
1,790
+104
+6% +$48.5K 0.14% 178
2024
Q4 		$679K Buy
1,686
+80
+5% +$37.1K 0.1% 193
2024
Q3 		$747K Buy
1,606
+28
+2% +$13.4K 0.12% 180
2024
Q2 		$740K Buy
1,578
+174
+12% +$75.5K 0.13% 173
2024
Q1 		$587K Buy
1,404
+18
+1% +$7.61K 0.11% 185
2023
Q4 		$564K Buy
+1,386
New +$512K 0.12% 175

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Premier Path Wealth Partners's VRTX Position: Q2 2026 in Review

Premier Path Wealth Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 6.4% in Q2 2026, selling an estimated $52.7K and leaving 1,751 shares worth $870K. The position accounts for 0.1% of the portfolio, ranked #185.

Premier Path Wealth Partners first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Premier Path Wealth Partners held 1,751 shares of Vertex Pharmaceuticals worth $870K as of Q2 2026.
  • Premier Path Wealth Partners sold 119 Vertex Pharmaceuticals shares in Q2 2026, an estimated $52.7K.
  • Vertex Pharmaceuticals made up 0.1% of Premier Path Wealth Partners's portfolio in Q2 2026, its #185 holding.
  • Premier Path Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Premier Path Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.